Bessemer Group
KPTI icon

Bessemer Group’s Karyopharm Therapeutics KPTI Stock Holding History

Bessemer Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-167
Closed -$22K – 1380
2016
Q1 		$22K Buy
+167
New +$18.4K ﹤0.01% 1045

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bessemer Group's KPTI Position: Q2 2016 in Review

Bessemer Group sold out of Karyopharm Therapeutics (KPTI) in Q2 2016, closing a stake of 167 shares — an estimated $22K sold.

Bessemer Group first reported a position in KPTI in Q1 2016 and held it in 1 quarter. The position peaked at $22K in Q1 2016. 75 funds tracked by Wall St. Rank hold KPTI as of Q2 2016.

  • Bessemer Group reported no remaining Karyopharm Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Bessemer Group sold 167 Karyopharm Therapeutics shares in Q2 2016, an estimated $22K.
  • Bessemer Group first reported a position in Karyopharm Therapeutics in Q1 2016 and held it in 1 quarter.
  • Bessemer Group's Karyopharm Therapeutics position peaked at $22K in Q1 2016.
  • 75 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.